Veil Therapeutics

  • Biotech or pharma, therapeutic R&D

Veil Therapeutics is developing VTX-101, a polymer-conjugated enzyme, for the treatment of chronic refractory gout. This preclinical program is enabled by Veil's proprietary stealth polymer platform which retains the PK/PD and stability benefits of PEGylation with a significantly reduced immunogenicity profile. Veil's internal pipeline is focused on protein - polymer conjugates and is looking for partnerships around novel peptide, lipid nanoparticle (LNP), and RNA aptamer - polymer conjugates.

Address

Durham
North Carolina
United States

Contact Exhibitor


Loading
View all Partnering Companies

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS